[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]

Rev Esp Patol. Jul-Sep 2020;53(3):167-181. doi: 10.1016/j.patol.2019.11.004. Epub 2020 Jun 16.
[Article in Spanish]


In 2011, the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) initiated a joint project to establish guidelines for biomarker testing in patients with advanced non-small-cell lung cancer based on the information available at the time. As this field is constantly evolving, these guidelines were updated in 2012 and 2015 and now in 2019. Current evidence suggests it should be mandatory to test all patients with this kind of advanced lung cancer for EGFR and BRAF mutations, ALK and ROS1 rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). However, the coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remain a challenge.

Keywords: ALK; BRAF; Biomarcadores; Biomarkers; Cáncer de pulmón de célula no pequeña; EGFR; Non-small-cell lung cancer; PD-L1; ROS1.

Publication types

  • English Abstract
  • Review